Vitek2 may deduce false susceptibility to cefixime in Staphylococcus

References

1. Barry J., Brown A., Ensor V., Lakhani U., Petts D., Warren C., Winstanley T. 2003; Comparative evaluation of the VITEK 2 Advanced Expert System (AES) in five UK hospitals. J Antimicrob Chemother 51:1191–1202 [View Article][PubMed]
   [Google Scholar]
2. Girish C., Balakrishnan S. 2011; Ceftaroline fosamil: a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin. J Pharmacol Pharmacother 2:209–211 [View Article][PubMed]
   [Google Scholar]
3. Macdonald A., Dow G. 2010; Ceftobiprole: first reported experience in osteomyelitis. Can J Infect Dis Med Microbiol 21:138–140[PubMed]
   [Google Scholar]
4. Neu H. C. 1987; In vitro activity of a new broad spectrum, β-lactamase-stable oral cephalosporin, cefixime. Pediatr Infect Dis J 6:958–962 [View Article][PubMed]
   [Google Scholar]
5. Sanders C. C., Peyret M., Moland E. S., Cavalieri S. J., Shubert C., Thomson K. S., Boeufgras J. M., Sanders W. E. Jr 2001; Potential impact of the VITEK2 system and the Advanced Expert System on the clinical laboratory of a university-based hospital. J Clin Microbiol 39:2379–2385 [View Article][PubMed]
   [Google Scholar]
6. Savini V., Catavitello C., Masciarelli G., Astolfi D., Balbinot A., Bianco A., Febbo F., D’Amario C., D’Antonio D. 2010; Drug sensitivity and clinical impact of members of the genus Kocuria. J Med Microbiol 59:1395–1402 [View Article][PubMed]
   [Google Scholar]
7. Shenep J. L., Flynn P. M., Baker D. K., Hetherington S. V., Hudson M. M., Hughes W. T., Patrick C. C., Roberson P. K., Sandlund J. T. other authors 2001; Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clin Infect Dis 32:36–43 [View Article][PubMed]
   [Google Scholar]